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http://dx.doi.org/10.1016/j.ccr.2013.09.008SUMMARYUnderstanding the mechanism by which tumor cells influence osteoclast differentiation is crucial for
improving treatment of osteolytic metastasis. Here, we report broad microRNA (miRNA) expression changes
in differentiating osteoclasts after exposure to tumor-conditioned media, in part through activation of NFkB
signaling by soluble intracellular adhesion molecule (sICAM1) secreted from bone-metastatic cancer cells.
Ectopic expression of multiple miRNAs downregulated during osteoclastogenesis suppresses osteoclast
differentiation by targeting important osteoclast genes. Intravenous delivery of these miRNAs in vivo inhibits
osteoclast activity and reduces osteolytic bone metastasis. Importantly, serum levels of sICAM1 and two
osteoclast miRNAs, miR-16 and miR-378, which are elevated in osteoclast differentiation, correlate with
bone metastasis burden. These findings establish miRNAs as potential therapeutic targets and clinical bio-
markers of bone metastasis.INTRODUCTION
Osteolytic bonemetastasis is a frequent occurrence in late stage
breast, lung, thyroid, bladder, and many other cancers, leading
to pathological fractures, pain, and hypercalcemia (Weilbaecher
et al., 2011). The development of bone lesions depends upon the
orchestrated interactions between tumor cells and functional
cells within the bone, namely osteoblasts and osteoclasts (Ell
and Kang, 2012; Weilbaecher et al., 2011). The bone resorbing
osteoclasts play an important role in physiological bone remod-Significance
The activation and recruitment of osteoclasts is of vital importa
nificant advances have been made in understanding tumor-stro
tiation. However, the role of miRNAs in osteoclastogenesis du
that tumor-conditioned media frommultiple cancer types activ
This signature includes upregulated miRNAs that correlate with
markers. Importantly, functional studies reveal impaired osteoc
ectopic expression of downregulated miR-141 and miR-219.
osteoclastogenesis and potential therapeutic targets and biom
542 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.eling (Boyle et al., 2003; Teitelbaum and Ross, 2003), whereas
aberrant osteoclast activity can lead to pathological conditions
including Paget’s disease and lytic bone metastasis (Weil-
baecher et al., 2011). Osteoclast differentiation is canonically
dependent on two essential molecules, macrophage colony-
stimulating factor (M-CSF) and receptor activator of NF-kB
ligand (RANKL) (Boyle et al., 2003; Teitelbaum and Ross,
2003), although a number of RANKL independent pathways
have been described (Hemingway et al., 2011). Aberrant expres-
sion of these signaling molecules by bone-metastatic cancernce for the development of osteolytic bone metastasis. Sig-
mal interactions that foster hyperactive osteoclast differen-
ring bone metastasis remains poorly understood. We show
ates a consensus miRNA response signature in osteoclasts.
bone metastasis burden and show potential as clinical bio-
last development and reduced bonemetastasis burden after
These findings establish miRNAs as essential regulators of
arkers during bone metastasis.
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Osteoclast miRNAs in Bone Metastasiscells has been shown to recruit preosteoclasts to the site of
osteolytic metastasis and induce their differentiation, leading to
degradation of the bone and the subsequent release of bone
matrix-embedded tumor-promoting growth factors such as
TGFb (Ell and Kang, 2012; Korpal et al., 2009; Weilbaecher
et al., 2011). The role of osteoclasts in bone metastasis is further
underscored by the efficacy of treatments targeting osteoclast
differentiation and activity (Cle´zardin, 2011).
MicroRNAs (miRNAs) are a class of short (22 nt) noncoding
RNAs capable of repressing gene expression through comple-
mentary binding of the ‘‘seed sequence’’ of target mRNAs (Bar-
tel, 2009). MiRNAs have been well recognized as playing vital
roles in cellular processes such as differentiation and develop-
ment (Kloosterman and Plasterk, 2006), and numerous studies
have linked aberrant miRNA expression to pathological condi-
tions such as cancer (Croce, 2009). Although a number of
miRNAs have been identified as regulators of metastasis (Le
et al., 2010), the function of miRNAs in organ-specific metastasis
to bone remains poorly understood. Furthermore, few studies to
date investigate the role of stromal miRNAs as potential media-
tors and biomarkers of metastasis. Given the prominent role of
osteoclasts in osteolytic bone metastasis, miRNAs that regulate
osteoclastogenesismay play a key role in osteolytic bonemetas-
tasis. Recent findings have revealed a general necessity for
miRNAs in osteoclastogenesis, as genetic or siRNA-mediated
ablation of factors important for biogenesis of miRNAs, including
Dicer1, Dgcr8, and Ago2, blocked osteoclast differentiation
(Mizoguchi et al., 2010; Sugatani and Hruska, 2009). Addition-
ally, ectopic expression of miR-155 (Mann et al., 2010; Mizogu-
chi et al., 2010; Zhang et al., 2012) or repression of miR-21
(Sugatani et al., 2011) inhibit osteoclast differentiation, whereas
conflicting functions of miR-223 in osteoclastogenesis have
also been reported (Sugatani and Hruska, 2007, 2009). Although
these results indicate a crucial role for miRNAs in physiological
osteoclast differentiation, a comprehensive understanding of
miRNAs in pathological osteoclastogenesis is needed to eval-
uate their potential application in clinical management of bone
metastasis. Here, we examine the miRNA expression changes
during physiological and pathological osteoclastogenesis and
evaluate the application of osteoclast miRNAs as possible ther-
apeutic targets and biomarkers for metastatic disease.
RESULTS
Conditioned Media from Bone-Metastatic Cancer Cells
Induces Osteoclast Differentiation
As previously shown (Sethi et al., 2011), the murine preosteo-
clast cell lines RAW264.7 (Figures S1A and S1B available online)
and MOCP-5 (data not shown) can be induced to differentiate
into mature, multinucleated osteoclasts through the addition of
20–50 ng/ml RANKL. To examine the potential for tumor-
conditioned media (CM) to induce osteoclast differentiation,
RAW264.7 or MOCP-5 preosteoclast cells were treated with
CM from two pairs of cancer cell lines with differing bone metas-
tasis capabilities: (1) the highly metastatic 4T1.2 mouse mam-
mary tumor cell line and weakly metastatic 4T1 parental line
(Lelekakis et al., 1999), and (2) the highly metastatic TSU-Pr1-
B2 human bladder cancer cell line and the weakly metastatic
TSU-Pr1 parental line (Chaffer et al., 2005). After 6 days of treat-Cment with CM, TRAP staining revealed mature osteoclasts only
in cells treated with CM from the highly bone metastatic 4T1.2
and TSU-Pr1-B2 (Figures 1A and 1B), although at significantly
lower levels than treatment with 50 ng/ml RANKL (RANKLHigh).
Combined treatment of RAW264.7 cells with CM and a limited
level of RANKL (20 ng/ml, RANKLLow) significantly increased dif-
ferentiation, approaching that seen by treatment with 50 ng/ml of
RANKL (Figures 1A–1C). Treatment with CM induced similar
differentiation in mouse bone marrow-derived primary preosteo-
clasts (Figure S1C) and MOCP5 cells (Figures S1D–S1F). Impor-
tantly, quantitative real-time reverse-transcriptase (RT)-PCR
indicated that osteoclast genes were elevated in RAW264.7 cells
upon treatment with RANKL and bone metastatic CM (Figures
S1G and S1H). Taken together, these results indicate that
bone-metastatic breast cancer cells are capable of secreting
factors that induce differentiation and maturation of osteoclasts.
MiRNA Microarrays Reveal Differentially Regulated
miRNAs
MiRNA microarray profiling was performed to compare miRNA
expression changes in RAW264.7 cells treated for 7 days with
CM from 4T1 versus 4T1.2 cells or CM from TSU-Pr1 versus
TSU-Pr1-B2 cells, and with or without 50 ng/ml RANKL. A total
of 334 mouse miRNAs were detected, revealing 42 upregulated
and 45 downregulated miRNAs with a >2.2-fold change across
treatment groups (Figure 1D, left panel). As an initial step toward
identifying miRNAs that may inhibit osteoclast differentiation, we
focused on 22 unique miRNAs consistently downregulated
across three sets of samples (Figure 1D, right panel). Notably,
there were significant correlations ofmiRNA expression changes
between the treatment groups (Figure 1E), indicating conserva-
tion in the miRNA regulatory network during osteoclastogenesis
in physiological and pathological conditions.
Genes known to be important for osteoclast differentiation and
function were examined for predicted miRNA binding sites
based on TargetScan (Grimson et al., 2007) and PicTar (Krek
et al., 2005) predictions (Table S1). Five miRNAs, miR-33a-5p,
miR-133a, miR-141-3p, miR-190, and miR-219-5p (hereafter
miR-33a, miR-141, and miR-219) were selected for further anal-
ysis based upon their significant downregulation, multiple pre-
dicted osteoclast targets, and sequence conservation between
human and mouse. Quantitative real-time RT-PCR analysis
confirmed that all five miRNAs examined decreased significantly
after 6 days of RANKL treatment in RAW264.7, primary bone
marrow-derived precursors (Figure 1F) and MOCP-5 cells (data
not shown). Importantly, these miRNA changes were also
observed during the differentiation of primary human osteoclasts
(Figures S1I–S1K).
Ectopic Expression of miRNAs Inhibits Osteoclast
Differentiation
To examine the functional role of the downregulated miRNAs
in osteoclastogenesis, we ectopically expressed the miRNAs
in preosteoclast cells prior to RANKL-induced osteoclast
differentiation. Overexpression of all five miRNAs resulted in
a significant decrease in osteoclast differentiation in both
RAW264.7 cells (Figure 2A) and primary preosteoclasts (Fig-
ure S2A). We observed no change in cell growth or apoptosis
after any of the miRNA treatments (data not shown). The defectancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc. 543
4T1 TSU RANKL 4T1 TSU RANKL
4
3
2
1
0
-1
-2
-3
-4
5
-5
miR-219
miR-141
miR-133a
miR-208
miR-190
miR-520a*
miR-33
miR-369-3p
miR-153
miR-32
miR-144
miR-135a
miR-154
miR-148a
miR-335
miR-376a*
miR-429
miR-186
miR-140
miR-651
miR-1
miR-522
DA
4T1 vs TSU 4T1 vs RANKL TSU vs RANKL
R2=0.66613R2 R81717.0= 2=0.66561
miR-141miR-133amiR-33a miR-190 miR-219FE
0
0.2
0.4
0.6
0.8
1.0
*
***
m
iR
N
A
ex
pr
es
si
on
Days post treatment
2 60
0
0.2
0.4
0.6
0.8
1.0
Days post treatment
2 60
*
***
B
O
st
eo
cl
as
ts
/fi
el
d
N
uc
le
i/o
st
eo
cl
as
t
0
2
4
6
8
10 **
0
12
3
9
6 **
**
*
C
RAW264.7 Primary osteoclasts
****
m
iR
N
A
ex
pr
es
si
on5
5
-5
-5
5
-5
5-5
5
-5
5-5
4T1 CM
TSU-Pr CM
4T1.2 CM
TSU-B2 CM
4T1.2 + RANKLLow
TSU-B2 + RANKLLow
RANKLLow
RANKLHigh
4T
1.
2
TS
U
-P
r1
TS
U
-B
2
4T
1.
2+
R
Lo
w
B
2+
R
Lo
w
4T
1
R
A
N
K
LL
ow
R
A
N
K
LH
Ig
h
***
**
** *
4T
1.
2
TS
U
-P
r1
TS
U
-B
2
4T
1.
2+
R
Lo
w
B
2+
R
Lo
w
4T
1
R
A
N
K
LL
ow
R
A
N
K
LH
Ig
h
Figure 1. RANKL and Conditioned Media of Highly Bone Metastatic Cancer Cell Lines Induce Similar Changes in miRNA Expression in
Osteoclasts
(A) Representative images of RAW264.7 cells stained for TRAP (red) after treatment for 6 days with conditioned media from indicated cell lines, or conditioned
media with 20 ng/ml RANKL (RANKLLow), or 50 ng/ml RANKL (RANKLHigh). Scale bar represents 200 mm.
(B) Quantification of TRAP+ osteoclasts from experiments in (A). **p < 0.01, ***p < 0.001.
(C) Quantification of nuclei in TRAP+ osteoclasts from experiments in (A). *p < 0.05, **p < 0.01.
(D) Heat map depictingmiRNAmicroarray expression profiling in RAW264.7 cells treated with conditionedmedia from 4T1.2 or TSU-Pr1-B2 cells as compared to
corresponding weakly metastatic cells (4T1 and TSU-Pr1), or 50 ng/ml RANKL as compared to nontreatment control.
(E) Correlation of miRNA expression changes in the indicated treatment pairs as in (D). Red dots represent miRNAs selected for further analysis.
(F) Quantitative real-time RT-PCR analysis of selected miRNAs in RAW264.7 or primary bonemarrow-derived osteoclasts after indicated length of treatment with
50 ng/ml RANKL. *p < 0.05, ***p < 0.001. Data in the figure represent average ± SEM; p values were based on Student’s t test.
See also Figure S1 and Table S1.
Cancer Cell
Osteoclast miRNAs in Bone Metastasisin osteoclastogenesis was confirmed by quantitative real-time
RT-PCR analysis that found repression of multiple osteoclast
marker genes after ectopic miRNA expression (Figure S2B).
In vitro bone resorption assay was then used to measure the
effect of ectopic miRNA expression on osteoclast activity. Inter-
estingly, althoughmiR-33a caused only a small decrease in bone
resorption, the remaining four miRNAs dramatically limited oste-
oclast activity (Figure 2B).
Because these miRNAs might inhibit osteoclast differentiation
or function by targeting different mRNAs, we further examined
the repression of osteoclast differentiation using combinations
of inhibitory miRNAs. Given that transient transfection with
10 pM of miRNA precursors was sufficient to inhibit up to544 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.90% of osteoclast differentiation, we treated RAW264.7 cells
with a combination of miRNAs at a reduced concentration of
1 pM total precursors. Combined ectopic expression of miR-
141, miR-190, and miR-219 revealed a significant additive effect
on osteoclast maturation (Figure 2C) and bone resorption (Fig-
ures 2D and S2C) that is equivalent to the treatment with
20 nM zoledronic acid (Figures 2D and S2C). Importantly,
ectopic expression of the miRNAs combined with zoledronic
acid revealed an additive effect, leading to almost complete
ablation of osteoclast activity (Figures 2D and S2C). These re-
sults reveal a necessity for repression of multiple miRNAs during
osteoclast differentiation, with ectopic expression of miR-133a,
miR-141, and miR-219 strongly inhibiting osteoclast maturation
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Figure 2. Ectopic Expression of miRNAs Downregulated during Osteoclastogenesis Inhibits Osteoclast Differentiation
(A) Quantification and representative images of TRAP+ osteoclasts in RAW264.7 cells transfected with indicated miRNAs followed by treatment with 50 ng/ml
RANKL. Scale bar represents 200 mm. **p < 0.01.
(B) Quantification and representative images of bone resorption by RAW264.7 cells after treatment in conditions as in (A), relative to control cells. Scale bar
represents 200 mm. **p < 0.01, ***p < 0.001.
(C) Quantification of TRAP+ osteoclasts from RAW264.7-treated cells transfected with 1 pM indicated miRNAs, followed by treatment with 20 ng/ml RANKL.
*p < 0.05.
(D) Quantification of relative bone resorption in RAW264.7 cells transfected with 1 pM indicated miRNA or 20 nM Zometa. *p < 0.05. Data in the figure represent
average ± SEM; p values were based on Student’s t test.
See also Figure S2.
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E F
Figure 3. Validation of Candidate miRNA Genes
(A–D) Normalized activity of the luciferase reporter containing the 30 UTR of candidate genes upon cotransfection with indicated miRNAs, relative to transfection
with negative control miRNA, is shown. *p < 0.05.
(E) Schematic indicating miRNA targets that are involved in osteoclast differentiation or function.
(F)Western blot analysis for Pu.1, Nfatc1, or Ctsk in RAW264.7 cells after transient transfection with indicatedmiRNA and treatment with 50 ng/ml RANKL. Data in
the figure represent average ± SEM; p values were based on Student’s t test.
See also Table S2.
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Osteoclast miRNAs in Bone Metastasisand activity in all models tested and partial inhibition seen after
ectopic expression of miR-33a and miR-190.
To confirm that miRNA-mediated inhibition of osteoclast dif-
ferentiation is not specific to the RAW264.7 model, we examined
the effect of ectopic miRNA expression in additional models.
MOCP5 cells transfected with pre-miRNAs revealed a similar
pattern of inhibition (Figures S2D and S2E). A previous study
revealed greatly enhanced osteoclast differentiation after activa-
tion of the Notch pathway by tumor-derived Jagged1 (Sethi
et al., 2011). To examine the effect of miRNAs on Jagged1-
enhanced osteoclast differentiation, RAW264.7 cells were
plated on Jagged1-coated plates, followed by treatment with
50 ng/ml RANKL. Ectopic miRNA expression significantly in-
hibited Jagged1-dependent enhancement of osteoclast dif-
ferentiation (Figures S2F–S2H). Taken together, these results
illustrate the broad capacity for ectopic expression of these
miRNAs to inhibit osteoclast differentiation.
Identification of miRNA Targets Involved in Osteoclast
Differentiation and Function
We sought to examine direct miRNA targeting of mRNAs related
to osteoclastogenesis using luciferase reporters containing the546 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.30UTR of prospective target mRNAs (Table S2). Reporter con-
structs were cotransfected with pre-miRs, as well as a Renilla
luciferase plasmid for normalization. Reporter assays revealed
a number of direct targets for the candidate miRNAs. MiR-
133a, miR-141, and miR-219 were all found to repress expres-
sion of Mitf, and specific targeting of Mitf by these miRNAs
was confirmed by site-directed mutagenesis of the predicted
miRNA binding sites (Figures 3A–SC). Interestingly, miR-141
was found to contain two active binding sites in the Mitf
30UTR, reducing expression by 50% (Figure 3B), whereas a
single site in miR-219 was able to repress Mitf expression by
20% (Figure 3C). In addition, miR-133a was found to repress
Mmp14, miR-141 repressed Calcr, miR-219 repressed Traf6,
and miR-190 was able to repress Calcr (Figures 3A–3D). These
miRNA targets represent important factors involved in osteoclast
differentiation and function, withMitf functioning as an essential
transcription factor, Calcr and Traf6 serving as important signal
transducers, andMmp14 functioning as a secretedmatrixmetal-
loproteinase during osteoclastogenesis (Figure 3E). To better
examine the capacity of the miRNAs to inhibit osteoclast differ-
entiation, osteoclast markers were examined in RAW264.7 cells
transfected with the miRNA of interest, followed by RANKL
Cancer Cell
Osteoclast miRNAs in Bone Metastasistreatment. Western blot analysis of Pu.1, Nfatc1, and Ctsk re-
vealed that miR-133a, miR-141, and miR-219 seem to be inhib-
iting early osteoclast differentiation, with minimal expression of
Nfatc1, which plays a role in early osteoclast commitment, or
the mature osteoclast marker Ctsk (Teitelbaum and Ross,
2003) (Figure 3F). These results are in agreement with their tar-
geting of Mitf or Traf6, either of which is predicted to inhibit the
earliest stages of osteoclast commitment. In comparison, miR-
190 transfected cells expressed Pu.1 and Nfatc1, but not Ctsk,
indicating that miR-190 might be inhibiting osteoclast differenti-
ation after commitment to an osteoclast fate. miR-33a-trans-
fected cells retained expression of all three osteoclast genes,
consistent with its relatively weak effect on inhibiting osteoclas-
togenesis (Figure 3F). Taken together, these results indicate that
the miRNAs are inhibiting osteoclast differentiation through the
functional targeting of essential osteoclast genes functioning at
different stages of osteoclast differentiation.
Systemic miRNA Treatment Inhibits Osteoclasts In Vivo
To evaluate the capacity for thesemiRNAs to inhibit mouse oste-
oclast function in vivo, we injected 10 mg of pre-miRNA into the
lateral tail-vein of Balb/c mice weekly for 4 weeks. Mice were
examined weekly by X-ray radiography, revealing increased
bone density in the hind limbs, particularly in the distal femur
and proximal tibia (data not shown). Examination by microCT
revealed increased trabecular bone in both femur and tibia
(Figure 4A). Further quantitative analyses confirmed a significant
increase in bone volume (Figure 4B) and trabecular thickness
(Figure 4C), whereas no significant differences in cortical bone
thickness was found (Figures 4A and 4D).
Histological TRAP staining of decalcified bone sections re-
vealed a significant decrease in the number of osteoclasts
relative to bone surface area in mice treated with miR-141 and
miR-219 (Figures 4A and 4E) and Von Kossa staining revealed
the increase of calcified tissues (Figure 4A), confirming the
significant expansion in trabecular bone that was seen in the
microcomputed tomography (microCT) analysis. Osteocalcin
immunohistochemical staining revealed no significant difference
in osteoblast number (Figures 4A and 4F), which is consistent
with a previous report that inhibition of miRNA biogenesis does
not affect osteoblast differentiation (Mizoguchi et al., 2010).
Although these results indicated osteoclasts as a major bone
cell type affected by systemic delivery of these miRNAs, it is
important to note that the differentiation or activity of additional
bone stromal cells might also be impacted.
MiR-141 and miR-219 Inhibit Experimental Bone
Metastasis
Given the ability of multiple miRNAs to inhibit osteoclast differen-
tiation in vitro and in vivo, we next examined the capacity of
these miRNAs to inhibit breast cancer bone metastasis in a
mouse model. We first examined the potential of CM from multi-
ple SCP cell lines, clonal derivatives of the human MDA-MB-231
breast cancer line (Kang et al., 2003) with different bonemetasta-
tic capabilities, to regulate osteoclast differentiation. Similar to
our previous results (Blanco et al., 2012), CM from highly bone
metastatic SCP cell lines (SCP2, SCP28, and SCP46), but not
from weakly metastatic lines (SCP4, SCP6, and parental MDA-
MB-231), stimulated osteoclast differentiation in RAW264.7 cellsC(Figures S3A and S3B), increased the expression of osteoclast
marker genes (Figure S3C), and induced miRNA expression
changes consistent with our previous findings (Figure S3D). After
further validating the ability of highly metastatic SCP28 to induce
osteoclastogenesis in MOCP5 cells (Figures S3E–S3G), we used
SCP28 for analyzing the effect of miRNAs on bone metastasis
development in mice.
Nude mice were systemically treated with control or experi-
mental pre-miRNAs immediately before, and once per week
subsequently, after inoculation with SCP28 cells via intracardiac
injection. Metastatic progression was monitored by weekly
bioluminescence imaging (BLI) using a firefly luciferase reporter
stably expressed in the cell line. Whereas treatment with miR-
133a and miR-190 had no effect on metastatic progression by
BLI, there was a significant decrease in hind-limb tumor burden
after treatment with either miR-141 (p = 0.024) or miR-219
(p = 0.015) (Figures 5A and 5B). Quantitative real-time RT-PCR
analysis of serum samples from mice inoculated with the pre-
miRNAs revealed a substantial decrease in miR-190 and miR-
133a within 6 hr of injection, with nearly full clearance within
24 hr (Figure 5C). In contrast, miR-141 and miR-219 took sub-
stantially longer to clear from the serum, maintaining 20% of
the normalized expression at 24 hr. X-ray imaging revealed
decreased bone lesions in miR-141- and miR-219-treated
mice, whereas miR-190, miR-133a, and control pre-miRNA-in-
jected mice exhibited significant bone degradation (Figures 5A
and 5D). Histological analysis revealed a decrease in osteolysis
by hematoxylin and eosin (H&E) staining and a decrease in
TRAP+ osteoclast recruitment at the tumor-bone interface.
Consistent with the results in miRNA-treated healthy mice (Fig-
ure 4), miR-190-, miR-141-, and miR-219-treated mice showed
a significant decrease in TRAP+ osteoclast number (Figure 5E),
whereas there was no noticeable change in osteoblast number
from any of the treatments (Figures 5A and 5F). To rule out the
potential influence of the miRNAs on the growth or survival of
the SCP28 cells, we treated the cells with miRNAs in culture
and found no significant difference in proliferation (data not
shown). Taken together, these results reveal a significant
decrease in metastatic burden after systemic treatment with
miR-141 or miR-219, likely due to decreased osteoclast activity.
We further compared the therapeutic effect of miRNAs with
treatment of 100 mg/kg zoledronic acid (Zometa) (Figures S3H
and S3I). As expected, mice treated with Zometa experienced
a significant decrease in tumor burden, with an overall trend of
better response than individual miR-141 or miR-219 treatment,
although the difference did not reach statistical significance.
These results indicate that systemic treatment with miR-141
and miR-219 inhibits bone metastasis burden to a similar extent
as current therapeutics.
Serum miRNA Levels Correlate with Bone Metastasis
To further evaluate the function of miRNAs that change during
osteoclast differentiation we next examined a subset of four
miRNAs with significant upregulation during osteoclastogenesis
(miR-16, miR-211, miR-378, and Let-7a, Figure 1D). Interest-
ingly, we did not observe significant differences after ectopic
expression or repression of any of the candidate miRNAs tested,
although this result did not rule out the functional importance of
additional candidates that we have not tested so far. As miRNAsancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc. 547
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Figure 4. Microcomputed Tomography and Histological Analysis Revealing Alterations in Bone Homeostasis after Treatment of miRNAs
Downregulated in Osteoclastogenesis
(A) Representative X-ray, mCT, and histological images for TRAP, H&E, Von Kossa, or osteocalcin staining of bones from mice treated with indicated miRNAs.
Regions of interest for trabecular and cortical bone scan and analysis are marked by blue and red dashed lines, respectively. Scale bar represents 200 mm. n = 6.
(B) Quantification of bone volume relative to total volume from representative mCT scans in (A). n = 3. *p < 0.05.
(C) Quantification of trabecular thickness from representative mCT scans of mice treated with miRNAs as in (B). *p < 0.05.
(D) Quantification of cortical bone thickness from representative mCT scans as in (B).
(E) Quantification of TRAP+ osteoclasts from decalcified histological sections of hindlimbs from mice in (A). n = 6. *p < 0.05.
(F) Quantification of osteocalcin-positive osteoblasts from bone sections from mice in (A). Data in the figure represent average ± SEM; p values were based on
Student’s t test.
Cancer Cell
Osteoclast miRNAs in Bone Metastasisare often released from cells into circulation, miRNAs with
increased expression during osteoclastogenesis may potentially
serve as biomarkers for osteolytic bone metastasis. To evaluate
the possibility of using osteoclast miRNAs as biomarkers, we
examined the expression of miRNAs upregulated during osteo-
clastogenesis (Figure 1D) in serum samples of micewith different
bonemetastasis burdens. Serum samples were collected at 0, 7,
and 35 days from nude mice after intracardiac injection of highly
metastatic SCP2 cells and miRNA expression was analyzed by
quantitative real-time RT-PCR. Examination of multiple miRNAs
with the most dramatic increase during differentiation revealed548 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.consistently elevated expression of miR-378 and miR-16 at
35 days postinjection (Figure 6A). Similarly, only miR-378 and
miR-16 were elevated when we compared mice with low or
high bone metastatic tumor burden after inoculation with weakly
metastatic TSU-Pr1 or highly metastatic TSU-Pr1-B2 cell lines,
respectively (Figure 6B). Based on these findings, we examined
the expression of miR-378 and miR-16 in matched primary
(Primary) or bone-metastatic (BM) tumor samples from 12 breast
cancer patients. Both miR-16 and miR-378 have elevated
expression in bone metastases, reflecting the presence of oste-
oclasts (Figure 6C). Next, we analyzed the expression of these
Cancer Cell
Osteoclast miRNAs in Bone Metastasistwo miRNAs in serum samples of healthy female donors (HD) or
breast cancer patients with bone metastasis (BM) and again
observed significantly increased level of bothmiRNAs in patients
with bone metastasis (Figure 6D). Taken together, these results
indicated the potential for using these miRNAs as biomarkers
for bone metastasis progression.
Soluble ICAM1 from Metastatic Cells Enhances
Osteoclast Differentiation
Because tumor CM-induced osteoclastogenesis produced
similar miRNA changes to RANKL-induced physiological osteo-
clast differentiation, we decided to identify soluble factor(s) in
CM that promote osteoclast activation. First, we investigated
whether RANKL present in CM is accountable for such activities.
ELISA quantification of RANKL levels in CM samples revealed
very low levels (4–6 ng/ml) of RANKL even in highly metastatic
MDA-MB-231, 4T1, or TSU sublines, although these sublines
produced significantly higher levels of RANKL than their weakly
metastatic isogenic counterparts (Figure S4A). These levels of
RANKL are insufficient to induce osteoclast differentiation (see
Figures S1A and S1B). Furthermore, osteoclast differentiation
induced by 30 ng/ml RANKL is inhibited by more than 80% after
treatment with 200 ng/ml of OPG, a decoy receptor and inhibitor
of RANKL. In contrast, such treatment resulted in only 50% in-
hibition of CM induced osteoclast differentiation (Figures 7A and
S4B). These results indicated that additional factor(s), other than
RANKL, in the tumor CM play an important role in enhancing os-
teoclastogenesis. A number of RANKL-independent osteoclast
differentiation factors have been previously described, such as
IL-6, MIF-1a, PTHrP, TNFa, GM-CSF, and IGF (Weilbaecher
et al., 2011). To examine whether any of these or other cytokines
were secreted by the metastatic cells to induce osteoclastogen-
esis, we evaluated cytokine expression in CM from the three se-
ries of cell lines with differential bone metastatic abilities (Fig-
ure 7B). Interestingly, among the cytokines analyzed, only
soluble ICAM1 (sICAM1), the cleaved extracellular domain of
ICAM1, was consistently overexpressed in the highly metastatic
cell lines. Cell surface ICAM1 has been previously implicated in
osteoclast differentiation, and antibodies against ICAM1 reduce
osteoclast maturation (Harada et al., 1998; Kurachi et al., 1993).
However, the functional role and mechanism of tumor-derived
sICAM1 in osteoclastogenesis is unknown. Treatment of
RAW264.7 cells with 50 ng/ml sICAM1 and 50 ng/ml RANKL
together prompted osteoclast differentiation within 2 days,
whereas treatment with RANKL alone required 4 days for the
first mature osteoclasts to differentiate (Figure 7C). Analysis of
osteoclast marker genes confirmed that sICAM1 treatment,
together with 50 ng/ml RANKL, reduced the time necessary for
osteoclast differentiation compared to RANKL treatment alone,
although there was no difference in endpoint expression levels
for any of the mRNAs (Figure S4C). Although sICAM1 alone
was not sufficient to induce differentiation, it exhibited an addi-
tive effect on differentiation when combined with limiting con-
centrations of RANKL (10 ng/ml RANKL, Figure 7D) and a signif-
icant inhibition in the expression of miRNAs downregulated
during osteoclastogenesis, which was magnified after cotreat-
ment with RANKL (Figure 7E).
Because the ELISA results from CM samples revealed very
low RANKL concentrations that are insufficient to support oste-Coclast maturation, and treatment with sICAM1 and RANKL
revealed an additive effect, we hypothesized that CM-induced
differentiation was due to the combined effect of both secreted
factors. To test this, RAW264.7 cells were treated with 4 ng/ml
RANKL (equivalent to the level in tumor CM) and increasing con-
centrations of sICAM1. Although low levels of sICAM1 had no
effect on RAW264.7 cells in the presence of 4 ng/ml RANKL,
we observed high levels of TRAP+ osteoclasts after treatment
with 50 ng/ml sICAM1, approaching that of CM treatments (Fig-
ures 7F and S4D). Furthermore, when RAW264.7 cells were
cultured with a function blocking monoclonal antibody (mAb)
against ICAM1, they exhibited a dose-dependent decrease in
osteoclast differentiation (Figures 7G and S4E) induced by
SCP28 CM, whereas RANKL-induced osteoclastogenesis was
unaffected. Additionally, treating SCP28 CM with sICAM1 mAb
resulted in an additive inhibitory effect when combined with
OPG (Figure S4F), and ICAM1 mAb was able to inhibit the
bone resorbing activity of CM-treated RAW264.7 cells (Fig-
ure S4G). Finally, RAW264.7 cells treated with sICAM1 showed
increased migration in a dose-dependent manner, which was
once again inhibited by the ICAM1 mAb (Figure S4H).
Taken together, these results support a functional role for
sICAM1 as a crucial component of tumor CM in stimulating
osteoclastogenesis.
Previous studies have identified aLb2 and aMb2 integrins as
receptors of sICAM1 (Carlos and Harlan, 1994). Indeed, a func-
tion-blocking antibody against the b2 subunit inhibited SCP28
CM-induced, but not RANKL-induced, differentiation (Figures
8A and S4I). Analysis of RAW264.7 cells revealed strong expres-
sion of aM and b2 subunits on the cell surface and lower expres-
sion of aL (Figure 8B). Signaling through b2 integrins has been
previously shown to activate the NFkB pathway in neutrophils
under stimulation by GM-CSF or IL-6 (Kettritz et al., 2004),
although it is not known if sICAM1 can similarly activate NFkB.
We examined activation of the pathway bymonitoring the activa-
tion of an NFkB luciferase reporter (Figure 8C), degradation of
IkBa (Figure 8D), or phosphorylation of p65 (Figure S5A) in
RAW264.7 cells treated with TNFa, RANKL, or sICAM1 over
time and observed similar responses in these three treatment
conditions. SCP28 CM treatment also showed a decrease in
IkBa, which was inhibited by the addition of an antibody against
the b2 integrin or OPG (Figure 8E). Similarly, the b2 integrin anti-
body inhibited sICAM1-induced activation of NFkB (Figure S5B)
but had no effect on NFkB signaling in RANKL-treated cells.
Interestingly, although sICAM1-induced miRNA changes were
abrogated after RAW264.7 cells were treated with the IKK inhib-
itor PS1145 (Figure 8F), miRNA transfection did not affect NFkB
activation induced by TNFa, RANKL, or sICAM1 (Figures S5C
and S5D), suggesting that these miRNAs act downstream of
NFkB activation to influence osteoclastogenesis. Together,
these results implicate sICAM1 as a bone metastatic cell-
secreted factor that functions through b2 integrin and NFkB
signaling to enhance osteoclast differentiation in the presence
of low levels of RANKL.
Correlation of Serum sICAM1 and miRNA Expression in
Patients with Bone Metastasis
To further investigate the clinical significance of sICAM1 as a
tumor-derived factor in inducing osteoclastogenesis andancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc. 549
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Figure 5. Systemic Treatment with miRNAs Downregulated in Osteoclastogenesis Inhibits Bone Metastasis
(A) BLI, X-ray, osteocalcin, H&E, and TRAP images from mice inoculated with SCP28 breast cancer cells and treated with indicated miRNAs. BLI images show
three representative mice from each experimental group. White arrows indicate osteolytic bone lesions in the X-ray images. Scale bar represents 200 mm. N = 10.
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Cancer Cell
Osteoclast miRNAs in Bone Metastasis
550 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.
TS
U
-P
r1
TS
U
-B
2
*
*
N
or
m
al
iz
ed
m
iR
N
A
le
ve
ls
0
10
20
30
40
50
60
70
211 37892a16
Control
TSU-Pr1
TSU-Pr1-B2
B
Let-7a29a
*
D
ay
 7
D
ay
 3
5
N
or
m
al
iz
ed
m
iR
N
A
le
ve
ls
211 37892a
0
5
10
15
20
*
*
A
150 Let-7a
Day 7
Day 35
Control
16 29a
DC
N
or
m
al
iz
ed
m
iR
N
A
le
ve
ls
miR-16 miR-378
p < 0.01 p < 0.01
3
6
9
0 N
or
m
al
iz
ed
m
iR
N
A
le
ve
ls
Primary BM Primary BM
0
3
6
9
HD BM HD BM
p = 0.0236 p = 0.0403
miR-16 miR-378
Figure 6. Serum Levels of miRNAs Upregu-
lated during Osteoclastogenesis Correlate
with Bone Metastasis
(A) BLI and quantitative real-time RT-PCR ex-
pression analysis of miRNAs in mice after intra-
venous inoculation with SCP2 breast cancer cells.
Left: BLI images of two representative mice
at each time point. Right: quantitative real-time
RT-PCR for miRNA expression levels of miRNAs
derived from serum samples taken on indicated
day postinjection. Data represent average ± SEM;
N = 10; *p < 0.05 by Student’s t test.
(B) BLI and qRT-PCR expression analysis of
miRNAs in mice 28 days after intravenous inocu-
lation with TSU-Pr1 or TSU-Pr1-B2 bladder cancer
cells. Data represent average ± SEM; N = 10; *p <
0.05 by Student’s t test.
(C) Quantitative real-time RT-PCR miRNA ex-
pression analysis of matched micro-dissected
primary breast tumor (Primary) or bone metastasis
(BM) samples. n = 12. p Values based on Mann-
Whitney test.
(D) Quantitative real-time RT-PCR miRNA ex-
pression analysis of serum samples from healthy
donors (HD) or breast cancer patients with bone
metastasis (BM). HD, n = 21. BM, n = 38. p Values
based on Mann-Whitney test.
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analyzed the expression levels of sICAM1 in serum samples
collected from HD, disease-free breast cancer patients (DFP)
showing no occurrence of bone metastasis (samples taken
immediately following resection of the primary tumor), or breast
cancer patients with BM. Patients with bone metastases ex-
hibited significantly increased serum sICAM1 level compared
to healthy donors or disease-free patients (Figure 8G). Impor-
tantly, a strong correlation was seen between serum expression
of sICAM1 and miR-16 or miR-378 (Figure 8H) in bone metas-
tasis patients, whereas little correlation was seen in samples
from healthy donors.
To further investigate the diagnostic potential of miR-16 and
miR-378 as secreted biomarkers for osteolytic bone metastasis,
we compared the serumexpression of themiRNAs againstN-ter-(B) Normalized bone metastasis BLI signals from mice in (A). n = 10. **p < 0.01 by Mann-Whitney test.
(C) Quantitative real-time RT-PCR miRNA expression levels from serum samples of mice taken at indicated
(D) Quantification of osteolytic lesion area in hindlimbs from indicated experimental group. (n = 6) **p < 0.01
(E) Quantification of TRAP+ osteoclasts from histology in experiment from (A). **p < 0.01.
(F) Quantification of osteocalcin+ osteoblasts from histology in experiment from (A). Data in the figure represen
t test unless otherwise indicated.
See also Figure S3.
Cancer Cell 24, 542–556,minal telopeptide (NTX), a standard
marker of bone turnover. The sensitivity
and specificity of using serum levels of
miR-16, miR-378, sICAM1 and NTX,
alone or in combination, for detecting
bone metastasis were determined (Fig-
ures S5E and S5F). The diagnostic values
of miR-378 and sICAM1 were lower than
that of either miR-16 or NTX as individualvariables, and combining sICAM1 with NTX did not significantly
increase the value. In contrast, miR-16 revealed increased spec-
ificity over NTX, while maintaining a similar sensitivity. Impor-
tantly, the combination of miR-16 with NTX produced increased
sensitivity, with only a slight reduction in specificity (Figure S5F).
These findings underscored the clinical significance of elevated
sICAM1 and miR-16/-378 expression in the serum of bone
metastasis and suggest their potential use as biomarkers for
diagnosis of bone metastasis or predictive marker for anti-
ICAM1 therapeutics.
DISCUSSION
The present study provides experimental and clinical evi-
dence to support the role of miRNAs in osteoclast activationtimes after injection with miRNAs. **p < 0.01.
.
t average ± SEM; p values were based on Student’s
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Figure 7. Soluble ICAM1 in Tumor-Conditioned Media Synergizes with RANKL to Promote Osteoclast Differentiation
(A) Quantification of RAW264.7 cells treated with 30 ng/ml RANKL or conditioned media ± 200 ng/ml OPG. **p < 0.01.
(B) Heat map from cytokine array depicting relative protein expression in conditioned media from indicated cell lines as compared to their weakly metastatic
counterparts (4T1 versus 4T1.2, TSU-Pr1 versus TSU-PR1-B2, and MDA-231 versus SCP28, respectively).
(C) Quantification of TRAP+ osteoclasts from RAW264.7 cells treated with 50 ng/ml RANKL ± 50 ng/ml sICAM1 for indicated length of time. ***p < 0.001.
(D) Quantification of TRAP+ osteoclasts from RAW264.7 cells treated with 10 ng/ml RANKL, 50 ng/ml sICAM1, or both for 6 days. *p < 0.05.
(E) Quantitative real-time RT-PCR analysis of selected miRNAs in RAW264.7 cells after indicated length of treatment with 10 ng/ml RANKL or/and 50 ng/ml
sICAM1. *p < 0.05 by ANOVA for all miRNAs.
(F) Quantification of osteoclasts/field and nuclei/osteoclast in RAW264.7 cells treated with 4 ng/ml RANKL plus indicated concentration of sICAM1 for 6 days.
**p < 0.01, ***p < 0.001.
(G) Quantification of TRAP+ osteoclasts from RAW264.7 cells treated with 30 ng/ml RANKL or SCP28-conditioned media followed by treatment with indicated
concentration of ICAM1 antibody (in mg/ml). *p < 0.05, **p < 0.01. Data in the figure represent average ± SEM; p values were based on Student’s t test unless
otherwise indicated.
See also Figure S4.
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Dicer in the osteoclast lineage has clearly established the
importance of miRNAs in physiological osteoclast development
(Mizoguchi et al., 2010; Sugatani and Hruska, 2009). How-
ever, little is known about miRNA regulation during tumor-
induced osteoclastogenesis. In this study, we revealed con-
sistent up- and downregulated miRNAs during osteoclast
differentiation in both physiological and pathological condi-
tions. We demonstrated inhibition of osteoclast differentiation
and osteolytic bone metastasis after ectopic expression of
several miRNAs downregulated during osteoclastogenesis.
We further identified sICAM1 as an important tumor-secreted
factor that enhances osteoclast differentiation and influences
osteoclast miRNA expression via the NFkB pathway. Impor-
tantly, serum levels of both sICAM1 and miRNAs are indicators
of bone metastasis burden in breast cancer patients. These552 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.results suggest multiple avenues for clinical translation of the
findings.
A previous microarray-based analysis of miRNA expression
changes in mouse primary osteoclasts was conducted 24 hr
after M-CSF/RANKL treatment and revealed altered expression
of dozens of miRNAs (Sugatani et al., 2011). In our current study,
we focus on miRNA changes induced by both RANKL and
tumor-conditioned media, and samples were collected after
7 days of treatment with RANKL or CM, after we observed full
osteoclast differentiation. Such analysis is likely to reveal not
only miRNAs involved in regulating osteoclast differentiation,
but also those that influence the function of mature osteoclasts.
Notably, although our miRNA microarray analysis revealed
similar trends of expression changed in miRNAs reported in
the previous study (Sugatani et al., 2011) (Figure S5G), a distinct
set of most differentially expressed miRNAs were identified in
A B C
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G H
Figure 8. sICAM1 Promotes Osteoclastogenesis by Activating NFkB Signaling, and sICAM1 Levels in Patient Serum Samples Are Correlated
with miR-16 and miR-378 Levels and Associated with Bone Metastasis
(A) Quantification of TRAP+ osteoclasts from RAW264.7 cells treated with RANKL or SCP28-conditioned media ± 20 mg ICAM1 antibody or 20 mg b2 integrin
antibody. Data represent average ± SEM; **p < 0.01 by Student’s t test.
(B) Expression of aL, aM, and b2 integrin subunits on RAW264.7 by IF (left) and flow cytometry (right). Scale bar represents 25 mm.
(C) Normalized activity of NFkB luciferase reporter in RAW264.7 cells after indicated treatment with TNFa, RANKL, or sICAM1 for indicated length of time. Data
represent average ± SEM.
(D) Western blot analysis of IkB in RAW264.7 cells after treatment with TNFa, RANKL, or sICAM1 for indicated length of time.
(E) Western blot analysis of IkB in RAW264.7 cells after treatment with indicated concentration of RANKL or SCP28 CM ± 20 ng b2 antibody or 200 ng/ml
OPG for 2 hr.
(F) Relative quantitative real-time RT-PCR miRNA expression level in RAW264.7 cells treated with 50 ng/ml sICAM1, with or without 20 mM IKK inhibitor PS1145
for 6 days, after normalization to the expression level without sICAM1 treatment. Data represent average ± SEM; *p < 0.05.
(G) ELISA quantification of sICAM1 expression levels in serum samples collected from healthy female donors (HD, n = 41), disease-free breast cancer patients
(DFP, n = 16), or breast cancer patients with bone metastasis (BM, n = 38). p Values based on Mann-Whitney test.
(H) Correlation of quantitative real-time RT-PCR miR-16 or miR-378 expression levels with ELISA sICAM1 protein expression levels in serum samples from
healthy donors or bone metastasis patients from (G).
See also Figure S5.
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two studies can be explained by the differences in cell lines
used, treatment conditions, and time points analyzed. Impor-
tantly, we used three different human and mouse cancer cell
lines from two different tumor types in the CM treatment exper-
iments. Despite the fact that these three distinctively different
tumor cells all secrete a subminimal amount of RANKL into their
CM, miRNA expression changes stimulated by their CM showed
high levels of consistency with RANKL-induced osteoclasto-
genesis. Moreover, ectopic overexpression of downregulated
miRNAs inhibited osteoclastogenesis induced bymultiple condi-Ctions, including RANKL, tumor CM, and Jagged1, in multiple
osteoclast cell lines or primary preosteoclasts. These findings
support a highly conserved miRNA regulatory network that con-
trols osteoclast differentiation in both pathological and physio-
logical conditions.
Our investigation into the functional target genes of osteo-
clast-inhibiting miRNAs revealed direct targeting of a number
of known osteoclast genes, including Mitf, Calcr, Traf6, and
Mmp14, by these miRNAs. MITF is a basic-helix-loop-helix-
zipper transcription factor (Hodgkinson et al., 1993) that is crucial
for osteoclast development (Hershey and Fisher, 2004; Sharmaancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc. 553
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Osteoclast miRNAs in Bone Metastasiset al., 2007; Weilbaecher et al., 2001). Traf6 encodes a member
of the tumor necrosis factor receptor (TNFR)-associated factor
family of cytokine receptor adaptor proteins that play an essen-
tial role in signaling transduction of the RANKL pathway (Lomaga
et al., 1999). Calcitonin receptor (CALCR) is a well characterized
cell-surface receptor capable of influencing osteoclast-medi-
ated bone resorption in vitro and in vivo (Davey et al., 2008).
Mmp14 knockout mice feature severe skeletal defects, including
osteopenia and skeletal dysplasia (Holmbeck et al., 1999). Inter-
estingly, additional studies have implicatedMmp14 in osteoclast
fusion during maturation, and Mmp14 null osteoclasts had
decreased activity in vitro (Gonzalo et al., 2010). Therefore,
decreased expression of Mitf, Traf6, Calcr, or Mmp14 is likely
to constitute a miRNA target gene network responsible for the
defect we see in osteoclast differentiation after ectopic expres-
sion of these miRNAs. Our analysis of stage-specific markers
of osteoclast differentiation revealed that miR-133a, miR-141,
and miR-219 seem to be inhibiting early osteoclastogenesis,
whereas miR-190 might inhibit osteoclast differentiation or func-
tion after commitment to an osteoclast fate.
CM from highly bone metastatic cells was able to induce oste-
oclast differentiation and miRNA expression changes despite
the presence of very low levels of RANKL, which is insufficient
to induce osteoclastogenesis. Importantly, we identified sICAM1
as a tumor-derived factor in the CM that enhances osteoclast
activation at the minimal concentration of RANKL. ICAM1 has
been previously observed to increase in expression level during
osteoclast differentiation, whereas ablation of ICAM1 inhibited
osteoclast differentiation from peripheral blood mononuclear
cells (Nakano et al., 2004). However, it was previously unknown
how tumor-derived sICAM1 influences osteoclast differentiation.
Our discovery that sICAM1 is capable of increasing RANKL-
induced osteoclast differentiation reveals an additional mecha-
nism for osteoclast regulation from bone metastatic cells and
suggests a potential target for therapeutic intervention. Various
tumor-derived factors have been previously shown to induce
osteoclast differentiation, including cell surface ligand Jagged1
and secreted factors RANKL, GM-CSF, MIP-1a, PTHrP, IL-8,
and IL-6 (Ell and Kang, 2012; Weilbaecher et al., 2011). Our find-
ings indicate a similar role for tumor-secreted ICAM1, which is
insufficient for independently inducing osteoclastogenesis but
capable of enhancing differentiation in the presence of low, but
physiological, levels of RANKL. We found that sICAM1 binding
to its cognate receptor b2 integrins activates NFkB signaling,
which is essential for canonical, RANK-mediated osteoclast dif-
ferentiation (Boyle et al., 2003; Teitelbaum and Ross, 2003),
potentially explaining the mechanism by which sICAM1 en-
hances osteoclast differentiation. Although it is not known how
b2 integrins activate the NFkB pathway, it has been proposed
that they provide a costimulatory effect on NFkB signaling in
neutrophils treated with GM-CSF or IL-8 (Kettritz et al., 2004).
Furthermore, b2 integrin clustering can activate NFkB (Kim
et al., 2004). Importantly, sICAM1-induced alterations in miRNA
expression appear to occur downstream of NFkB, as inhibiting
the pathway prevented miRNA changes, whereas none of the
miRNAs examined in this study altered NFkB signaling. Addition-
ally, sICAM1 increases the migration of preosteoclast cells,
which may indicate a role for bone-metastasis derived sICAM1
in the recruitment of osteoclasts to the developing bone lesion.554 Cancer Cell 24, 542–556, October 14, 2013 ª2013 Elsevier Inc.This hypothesis is in line with results from a previous study that
identified soluble VCAM1 as an important bone metastasis fac-
tor in the recruitment of osteoclasts to the osteolytic lesion
through the binding of a4b1 integrins on preosteoclast cells (Lu
et al., 2011). Notably, VCAM1 and ICAM1 are both endothelial
adhesion molecules of the Ig gene superfamily that bind leuko-
cyte integrins. It is therefore not surprising that they have
conserved functions in enhancing osteoclastogenesis in bone
metastasis.
Our findings reveal several avenues for potential translational
applications in the clinical management of bone metastasis.
Intravenous injection of pre-miR-133a, pre-miR-141, pre-miR-
190, or pre-miR-219 significantly reduced osteoclast activity
in vivo. These effects were seenmost clearly in the trabecular re-
gion of the femur and tibia, whereas no significant difference was
seen in cortical bone thickness. This finding is similar to the
observation in animals treated with bisphosphonates (Quattroc-
chi et al., 2012), possibly because of the higher rates of turnover
in the trabecular bone. Consistently, treatment of mice with the
pre-miR-141 and pre-miR-219 was capable of inhibiting osteo-
lytic bone metastasis. It is curious that miR-133a and miR-190
had no measurable effect on bone metastasis, despite a sub-
stantial influence on normal bone remodeling. It seems unlikely
that this is due to a tumor-intrinsic mechanism, because
in vitro studies showed no effect on SCP28 growth or survival
after miRNA treatment. Instead, is possible that this is explained
by the measured differences in stability of the miRNAs in circula-
tion, as inhibition of bone metastasis may require greater levels
of miRNAs to reach the bone than inhibition of normal bone
remodeling.
In our studies, systemic injection of unconjugated miRNAs
was sufficient to induce broad changes in bone remodeling
and appeared to be well-tolerated by the mice. Although our
data from in vitro and in vivo experiments illustrate miRNA-
mediated inhibition of osteoclasts, it is possible that these
miRNAs might also target additional cells in vivo. Therefore,
additional further analyses of other potential cellular and molec-
ular targets of these miRNAs during long-term treatment in vivo
should be conducted when developing potential miRNA-based
therapeutic applications. It is possible that improved delivery
methods might enhance the pharmacokinetics and efficacy
of the miRNAs on bone metastasis and potentially reveal an
effect from miR-133a and miR-190. The therapeutic effects of
miR-141 and miR-219 mimic those seen in mice after treatment
with Zometa. In addition, we noted an additive effect from
combined treatment with miR-141/-190/-219 and Zometa on
bone resorption in vitro. Thus, it is possible that combinatorial
treatments including miRNAs and currently approved osteo-
clast-targeting agents such as biosphosphonates and deno-
sumab (RANKL antibody) might provide enhanced clinical effi-
cacy. Furthermore, the functional role of tumor-derived sICAM1
in pathological osteoclast differentiation suggests the potential
for using ICAM1 blocking antibodies for targeted therapeutics.
Therefore, osteoclast miRNAs and sICAM1 represent potential
targets in the treatment of aberrant osteoclast activity, namely
bone degenerative diseases such as osteolytic bone metas-
tasis, osteoporosis, and Paget’s disease. Finally, our discovery
that miR-16 and miR-378 levels increase in bone lesions and
serum samples of bone metastasis patients presents the
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combined miR-16 and NTX as biomarkers increased the sensi-
tivity of bone metastasis diagnosis, although the potential clin-
ical application of this combination still awaits further large
scale prospective analysis.EXPERIMENTAL PROCEDURES
Tumor Xenografts and Bioluminescence Analysis
All procedures involving mice and experimental protocols were approved
by Institutional Animal Care and Use Committee (IACUC) of Princeton
University. For bone metastasis studies, 1 3 105 tumor cells were injected
into the left cardiac ventricle of anesthetized female athymic Ncr-nu/nu.
MiRNA precursors (10 mg/mouse in 100 ml PBS, Applied Biosystems) and
Zometa (100 mg/kg) were injected intravenously. Development of metastases
was monitored by measuring photon flux of BLI signals in the hindlimbs of
mice after retro-orbital injection of 75 mg/kg D-Luciferin and image acquisition
using the Xenogen IVIS 200 Imaging System. Data were normalized to the
signal on day 0. X-ray examination was performed as previously described
(Kang et al., 2003).Analysis of Primary Tumors and Bone Metastases
Women with resected breast cancer were selected from patients followed
from 1995 to 2010 in IRCCS IRST, Meldola, Italy. Tumor specimens were
de-identified and were considered exempt samples in accordance with the
institutional review board of the Local Ethic Committee, Forlı`, Italy. Tumor
specimens were fixed in formalin and embedded in paraffin. Tissues collected
were 13 matched primary breast tumors and 13 bone metastatic tissues. Total
RNA was collected from 20 mm thick sections from formalin-fixed paraffin
embedded (FFPE) tissue blocks using the FFPE RNA/DNA Purification kit
(Norgen) according to the manufacturer’s instructions.Serum Case Series and Sample Collection
Breast cancer patients with no evidence of disease for at least 5 years
(16 patients) and patients at first diagnosis of bone metastases (38 patients,
radiologically confirmed) were recruited by the Osteoncology and Rare
Tumors Center of IRCCS IRST (Meldola, Italy) from January 2007 to December
2009. A group of 41 healthy donors was also enrolled in the study. Informed
consent was obtained from all subjects in accordance with the protocol
approved by the institutional review board of the Local Ethic Committee, Forlı`,
Italy. A 5 ml venous blood sample from donors and patients was collected in
tubes without anticoagulant and centrifuged at 2,500 rpm for 15 min at room
temperature then stored at 80C until processing. Total RNA from 400 ml of
serum was extracted using the miRVana miRNA isolation kit (Ambion) accord-
ing to the manufacturer’s instructions.Statistical Analysis
Results are presented as average ± SD or as average ± SEM, as indicated in
figure legends. BLI signals were analyzed by nonparametric Mann-Whitney
test. For serum markers analysis, in the absence of internationally available
cut off values for markers, the cut off values maximally discriminating between
patients with no evidence of disease and BM patients were identified using
receiver operating characteristic (ROC) curve analysis. Sensitivity and
specificity were calculated, and their statistical significance was analyzed by
chi-square test comparing BM patients versus patients with no evidence of
disease or versus healthy donors. The correlation between serum levels of
the markers was assessed with the Spearman rank test. The diagnostic rele-
vance of the combinations NTX-mir16 and NTX-sICAM1 considered as contin-
uous variables (subjected to natural logarithmic transformation) was analyzed
by the logistic regression model. The linear predictor or logit resulting from
the model was used as a diagnostic test on which the ROC curve was
calculated (Flamini et al., 2006). Statistical analysis was done using SPSS soft-
ware. All other comparisons were analyzed by unpaired, two-sided, indepen-
dent Student’s t test without equal variance assumption, unless otherwise
described in figure legends.CACCESSION NUMBERS
The raw and normalized microarray data have been deposited in the Gene
Expression Omnibus (GEO) database under accession number GSE44936.
SUPPLEMENTAL INFORMATION
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